Cullinan Therapeutics (CGEM) Current Leases (2022 - 2026)

Cullinan Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $725000.0 for Q1 2026.

• In Q1 2026, Current Leases fell 46.18% year-over-year to $725000.0; the TTM figure through Mar 2026 stood at $725000.0 (down 46.18% YoY), while the FY2025 annual figure was $780000.0, down 40.09% from the prior year.
• Current Leases for Q1 2026 stood at $725000.0, down from $780000.0 in the prior quarter.
• The five-year high for Current Leases was $1.7 million in Q2 2023, with the low at $519000.0 in Q1 2022.
• The 5-year median for Current Leases is $1.3 million (2024), against an average of $1.2 million.
• The sharpest annual moves came in 2023 and 2026: Current Leases soared 209.94% in 2023, then sank 46.18% in 2026.
• Cullinan Therapeutics' Current Leases stood at $1.4 million in 2022, then gained by 1.34% to $1.4 million in 2023, then dropped by 9.58% to $1.3 million in 2024, then tumbled by 40.09% to $780000.0 in 2025, then dropped by 7.05% to $725000.0 in 2026.
• Business Quant data shows CGEM's Current Leases at $725000.0 in Q1 2026, $780000.0 in Q4 2025, and $1.2 million in Q3 2025.